Abstracts tagged "ANCA associated vasculitis"

Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
David Silverman¹, Timothy Barnes², Nnaemeka Odo², Jared Silver³, Lisa Le², Amy Edgecomb⁴ and Hitesh Patel⁵, ¹Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, ²Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, ³Clinical Development, Amgen, Thousand Oaks, California, ⁴Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, ⁵US Medical Affairs, GSK, Durham, North Carolina
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
Abstract Number: 2520 • ACR Convergence 2025
Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
Stefan Krämer¹, Kristian Vogt², Martin Busch³, Tobias Schmitt⁴, Raoul Bergner⁵, Sebastian Mosberger⁵, Thomas Neumann⁶, Teresa Schreibing¹, Fabian Schumbrink¹ and Thomas Rauen², ¹Department of Internal Medicine II, RWTH University Hospital Aachen, Aachen, Germany, ²Department of Internal Medicine II, RWTH University Hospital AachenMedicine II, Aachen, Germany, ³Department of Internal Medicine III, University Hospital, Friedrich-Schiller University, Jena, Jena, Germany, ⁴University Hospital Jena, Friedrich-Schiller University, Department of Internal Medicine III, Jena, Germany, ⁵Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁶Department of Rheumatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Glomerulonephritis is a common and threatening manifestation in ANCA-associated vasculitis (AAV). To assess the risk of end-stage kidney disease (ESKD), various scores have been…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…
Abstract Number: 1601 • ACR Convergence 2025
Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series
Helen Au¹, Christian Löffler², Hartmut Mahrhofer¹, Bastian Walz¹ and Bernhard Hellmich¹, ¹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ²Medizinische Klinik V, Nephrology, Endocrinology, Hypertensiology and Rheumatology, Universitaetsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
Background/Purpose: B-cell depletion with anti-CD20 therapy is the current cornerstone of management in organ- or life-threatening ANCA-associated vasculitis (AAV). Guidelines recommend the use of rituximab…
Abstract Number: 0717 • ACR Convergence 2025
Circulating Bacterial sRNAs are Altered in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Christopher Xavier¹, Kevin Byram², Carol Langford³ and Michelle Ormseth⁴, ¹Meharry Medical College, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Cleveland Clinic, Moreland Hills, OH, ⁴Vanderbilt University Medical Center, Nashville
Background/Purpose: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) is an autoimmune disease causing small vessel inflammation. Underlying mechanisms of disease are unclear, but the human microbiota may…
Abstract Number: 0421 • ACR Convergence 2025
Inflammatory Orbital Diseases: Pediatric Case Series From a Tertiary Care Center
Rasha Elrefai¹, Katherine Williams² and Hannah Bradfield³, ¹Baylor College of Medicine, Houston, TX, ²Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Orbital inflammatory diseases in the pediatric population present diagnostic and therapeutic challenges due to variable clinical manifestations, limited prospective data, and lack of standardized…
Abstract Number: 2518 • ACR Convergence 2025
Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study
Saloni Patel¹, Brendan Denvir², Maria Kaltchenko¹, Aaron Bao³, Varsha Simha¹, Michael Cammarata⁴ and Jun Kang⁵, ¹Johns Hopkins University School of Medicine, Baltimore, ²Johns Hopkins, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD, ⁴Johns Hopkins, Phoenix, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic small vessel vasculitis associated with significant morbidity and complex care needs across a broad demographic…
Abstract Number: 1767 • ACR Convergence 2025
Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis
Claire Galand¹, Fei Liu², Katherine Vernon², Ravi Vats², Christine Lian³, V. Michael Holers⁴, H. Terence Cook⁵, David Cuthbertson⁶, Nader Khalidi⁷, Curry Koening⁸, Carol Langford⁹, Carol McAlear¹⁰, Paul Monach¹¹, Christian Pagnoux¹², Jason Campagna², Shelia Violette² and Peter Merkel¹⁰, ¹Q³² Bio Inc,, Waltham, MA, ²Q³² Bio Inc, Waltham, MA, ³Department of Pathology, Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, ⁴University of Colorado Anschutz Medical Campus, Aurora, ⁵Department of Immunology and Inflammation, Imperial College London, London, United Kingdom, ⁶University of South Florida, Tampa, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Texas Dell Medical School, Austin, TX, ⁹Cleveland Clinic, Moreland Hills, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: One proposed mechanism of tissue damage in ANCA-associated vasculitis (AAV) is the formation of neutrophil extracellular traps (NETs) during extravasation of neutrophils into and…
Abstract Number: 1602 • ACR Convergence 2025
Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis
Irene Carrión-Barberà¹, Jorge A. Gonzalez-Chapa², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Kenneth Warrington¹², Peter Merkel⁷ and Christian Lood², ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²University of Washington, Division of Rheumatology, Seattle, ³University of South Florida, Tampa, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN
Background/Purpose: Innate immune activation plays a key role in granulomatosis with polyangiitis (GPA), contributing to vascular inflammation via neutrophil extracellular traps, immune complexation (IC), and…
Abstract Number: 0718 • ACR Convergence 2025
Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden
Hanna Lindberg¹, Klytaimnistra Voudouri¹, Lars Lindhagen¹, Maria K Svensson², Ann Knight¹ and Johanna Dahlqvist³, ¹Uppsala University, Uppsala, Sweden, ²Uppsala University, Uppsala, ³Uppsala University Hospital, Uppsala, Sweden
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk…
Abstract Number: 0150 • ACR Convergence 2025
Mortality in Anca-associated Vasculitis
Fabricio Benavides Villanueva¹, Vanesa Calvo-Río², Diana Prieto-Peña³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁸, maria Rodríguez-Vidriales⁸ and Ricardo Blanco², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Mortality rates are scare,…
Abstract Number: 2517 • ACR Convergence 2025
Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
Sai Shanmukha Sreeram Pannala¹, Medha Rajamanuri², Srikar Sama³, Fares Saliba⁴, Omar Mourad⁵, Koushik Varma Sangaraju⁶, Veena Katikineni⁷ and Anastasia Slobodnick⁸, ¹Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, staten island, new york city, NY, ²Southern Illinois University School of Medicine, Springfield, IL, ³University of California San Francisco Fresno, Fresno, CA, ⁴Staten Island University Hospital, Staten Island, NY, ⁵Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, ⁶St. Luke's University Health Network, Bethlehem, PA, ⁷Desert Orthopaedic and Rheumatologic Institute, Apple Valley, CA, ⁸Northwell, Staten Island, NY
Background/Purpose: Plasmapheresis (PLEX) has a compelling rationale in its ability to remove pathogenic ANCAs, in the management of ANCA-associated vasculitis (AAV), particularly in patients with…
Abstract Number: 1768 • ACR Convergence 2025
TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis
Lea Dionet¹, Alexandre Lanau², Paul Breillat³, Quentin Delcros⁴, Federica Pallotti⁵, Margot Poux⁶, Pierre Isnard¹, Arthur Lavigne⁴, Xavier Puéchal⁷, alexandre karras⁸, Jean-Paul Duong⁹, Olivia Lenoir¹⁰, Pierre-Louis Tharaux¹¹ and Benjamin Terrier¹², ¹INSERM, Paris, France, ²Institut Curie, Paris, France, ³INSERM, PARIS ¹⁷, Ile-de-France, France, ⁴AP-HP, Paris, France, ⁵Internal Medicine and Clinical Immunology, Rennes, France, ⁶Université de Paris, PARIS ⁰⁴EME, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁸HEGP - assistance publique hopitaux de paris, paris, France, ⁹INSERM, Paris, ¹⁰Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, Ile-de-France, France, ¹¹Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, France, ¹²Cochin Hospital, Paris, France
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-vessel vasculitis that can lead to life-threatening renal injury. Neutrophils, monocytes and macrophages play a pivotal role not only…
Abstract Number: 1600 • ACR Convergence 2025
Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study
Fabricio Benavides Villanueva¹, Andrea Tristan-Alonso², Carlos Martinez-Rivera³, Alicia Padilla-Galo⁴, Marina Blanco-Aparicio⁵ and Ricardo Blanco⁶, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Pneumology, Hospital Universitario Puerta del Hierro, Madrid, Spain, Majadahonda, Madrid, Spain, ³Division of Pneumology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁴Division of Pneumology, Hospital Universitario Virgen de la Victoria, Málaga, Spain, Malaga, Andalucia, Spain, ⁵Division of Pneumology, Hospital Universitario A Coruña, A Coruña, Spain, A coruña, Galicia, Spain, ⁶Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Benralizumab is approved for eosinophil-driven conditions, like eosinophilic asthma. Recently, the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) authorized its…
Abstract Number: 0716 • ACR Convergence 2025
Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis
Chelsea Cheng¹, Justine Lafleur-Careau², Navneet Kang¹, Medha Soowamber³ and Christian Pagnoux³, ¹Mount Sinai Hospital, Toronto, Canada, ²Mount Sinai Hospital, Saint-Augustin-de-Desmaures, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystem disorder characterized by asthma, rhinitis, peripheral blood eosinophilia, and necrotizing vasculitis of small vessels. Cardiac…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].